[HTML][HTML] SARS-CoV-2 variant biology: immune escape, transmission and fitness
AM Carabelli, TP Peacock, LG Thorne… - Nature Reviews …, 2023 - nature.com
In late 2020, after circulating for almost a year in the human population, severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) exhibited a major step change in its …
respiratory syndrome coronavirus 2 (SARS-CoV-2) exhibited a major step change in its …
A detailed overview of SARS-CoV-2 omicron: its sub-variants, mutations and pathophysiology, clinical characteristics, immunological landscape, immune escape, and …
The COVID-19 pandemic has created significant concern for everyone. Recent data from
many worldwide reports suggest that most infections are caused by the Omicron variant and …
many worldwide reports suggest that most infections are caused by the Omicron variant and …
Emergence of SARS-CoV-2 Omicron (B. 1.1. 529) variant, salient features, high global health concerns and strategies to counter it amid ongoing COVID-19 pandemic
Since the appearance in the late of December 2019, SARS-CoV-2 is rapidly evolving and
mutating continuously, giving rise to various variants with variable degrees of infectivity and …
mutating continuously, giving rise to various variants with variable degrees of infectivity and …
Limited cross-variant immunity from SARS-CoV-2 Omicron without vaccination
Abstract SARS-CoV-2 Delta and Omicron are globally relevant variants of concern. Although
individuals infected with Delta are at risk of developing severe lung disease, infection with …
individuals infected with Delta are at risk of developing severe lung disease, infection with …
Increased immune escape of the new SARS-CoV-2 variant of concern Omicron
J Hu, P Peng, X Cao, K Wu, J Chen, K Wang… - Cellular & Molecular …, 2022 - nature.com
On 24 November, a new detected variant B. 1.1. 529 of SARS-CoV-2 by South Africa was
reported to WHO. After only 2 days, this variant was designated as “variant of concern”(VOC) …
reported to WHO. After only 2 days, this variant was designated as “variant of concern”(VOC) …
Signals of significantly increased vaccine breakthrough, decreased hospitalization rates, and less severe disease in patients with coronavirus disease 2019 caused by …
Genetic variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
continue to dramatically alter the landscape of the coronavirus disease 2019 (COVID-19) …
continue to dramatically alter the landscape of the coronavirus disease 2019 (COVID-19) …
[HTML][HTML] Neutralizing immunity in vaccine breakthrough infections from the SARS-CoV-2 Omicron and Delta variants
V Servellita, AM Syed, MK Morris, N Brazer, P Saldhi… - Cell, 2022 - cell.com
Virus-like particle (VLP) and live virus assays were used to investigate neutralizing immunity
against Delta and Omicron SARS-CoV-2 variants in 259 samples from 128 vaccinated …
against Delta and Omicron SARS-CoV-2 variants in 259 samples from 128 vaccinated …
[HTML][HTML] Management of hospitalised adults with coronavirus disease 2019 (COVID-19): a European Respiratory Society living guideline
JD Chalmers, ML Crichton… - European respiratory …, 2021 - Eur Respiratory Soc
Introduction Hospitalised patients with coronavirus disease 2019 (COVID-19) as a result of
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection have a high …
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection have a high …
[HTML][HTML] Omicron (B. 1.1. 529) variant of SARS‐CoV‐2: concerns, challenges, and recent updates
Omicron (B.1.1.529) variant of SARS‐CoV‐2: Concerns, challenges, and recent updates -
PMC Back to Top Skip to main content NIH NLM Logo Access keys NCBI Homepage …
PMC Back to Top Skip to main content NIH NLM Logo Access keys NCBI Homepage …
Susceptibility of SARS-CoV-2 Omicron variants to therapeutic monoclonal antibodies: systematic review and meta-analysis
ABSTRACT SARS-CoV-2 Omicron variants contain many mutations in its spike receptor-
binding domain, the target of all authorized monoclonal antibodies (MAbs). Determining the …
binding domain, the target of all authorized monoclonal antibodies (MAbs). Determining the …